Last Updated : April 15, 2024
Details
Generic Name:
imiquimod
Project Status:
Withdrawn
Therapeutic Area:
Gynecological cancers
Manufacturer:
N/A
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0364-000
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
For the treatment of high grade squamous intraepithelial lesions (HSIL) (CIN 2 and 3) of the cervix and of Paget’s disease of the vulva.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Submission received | March 21, 2024 |
|---|---|
| Clarification: - Submission was voluntarily withdrawn by the Provincial Advisory Group (PAG) on 15-Apr-2024 | |
Last Updated : April 15, 2024